Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

The Influence of Biomarker Mutations and Systemic Treatment on Cerebral Metastases from NSCLC Treated with Radiosurgery

  • Lee, Min Ho (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kong, Doo-Sik (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Seol, Ho Jun (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Nam, Do-Hyun (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Jung-Il (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2016.04.11
  • Accepted : 2016.08.30
  • Published : 2017.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : The purpose of this study was to analyze outcomes and identify prognostic factors in patients with cerebral metastases from non-small cell lung cancer (NSCLC) treated with gamma knife radiosurgery (GKS) particularly, focusing on associations of biomarkers and systemic treatments. Methods : We retrospectively reviewed the medical records of 134 patients who underwent GKS for brain metastases due to NSCLC between January 2002 and December 2012. Representative biomarkers including epidermal growth factor receptor (EGFR) mutation, K-ras mutation, and anaplastic lymphoma kinase (ALK) mutation status were investigated. Results : The median overall survival after GKS was 22.0 months (95% confidence interval [CI], 8.8-35.1 months). During follow-up, 63 patients underwent salvage treatment after GKS. The median salvage treatment-free survival was 7.9 months (95% CI, 5.2-10.6 months). Multivariate analysis revealed that lower recursive partition analysis (RPA) class, small number of brain lesions, EGFR mutation (+), and ALK mutation (+) were independent positive prognostic factors associated with longer overall survival. Patients who received target agents 30 days after GKS experienced significant improvements in overall survival and salvage treatment-free survival than patients who never received target agents and patients who received target agents before GKS or within 30 days (median overall survival: 5.0 months vs. 18.2 months, and 48.0 months with p-value=0.026; median salvage treatment-free survival: 4.3 months vs. 6.1 months and 16.6 months with p-value=0.006, respectively). To assess the influence of target agents on the pattern of progression, cases that showed local recurrence and new lesion formation were analyzed according to target agents, but no significant effects were identified. Conclusion : The prognosis of patients with brain metastases of NSCLC after GKS significantly differed according to specific biomarkers (EGFR and ALK mutations). Our results show that target agents combined with GKS was related to significantly longer overall survival, and salvage treatment-free survival. However, target agents were not specifically associated with improved local control of the lesion treated by GKS either development of new lesions. Therefore, it seems that currently popular target agents do not affect brain lesions themselves, and can prolong survival by controlling systemic disease status.

Keywords

References

  1. Ahn HK, Jeon K, Yoo H, Han B, Lee SJ, Park H, et al. : Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer. J Thorac Oncol 8 : 250-253, 2013 https://doi.org/10.1097/JTO.0b013e3182746772
  2. Alexander E 3rd, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, et al. : Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87 : 34-40, 1995 https://doi.org/10.1093/jnci/87.1.34
  3. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. : Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363 : 1665-1672, 2004 https://doi.org/10.1016/S0140-6736(04)16250-8
  4. Baschnagel AM, Meyer KD, Chen PY, Krauss DJ, Olson RE, Pieper DR, et al. : Tumor volume as a predictor of survival and local control in patients with brain metastases treated with gamma knife surgery. J Neurosurg 119 : 1139-1144, 2013 https://doi.org/10.3171/2013.7.JNS13431
  5. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD : Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys 64 : 898-903, 2006 https://doi.org/10.1016/j.ijrobp.2005.08.035
  6. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, et al. : Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8 : 3250-3258, 2002
  7. Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC : Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg 122 : 548-553, 2001 https://doi.org/10.1067/mtc.2001.116201
  8. Bonnette P, Puyo P, Gabriel C, Giudicelli R, Regnard JF, Riquet M, et al. : Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 119 : 1469-1475, 2001 https://doi.org/10.1378/chest.119.5.1469
  9. Chidel MA, Suh JH, Greskovich JF, Kupelian PA, Barnett GH : Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis. Radiat Oncol Investig 7 : 313-319, 1999 https://doi.org/10.1002/(SICI)1520-6823(1999)7:5<313::AID-ROI7>3.0.CO;2-9
  10. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al. : Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65 : 3328-3335, 2005 https://doi.org/10.1158/0008-5472.CAN-04-3547
  11. Cho KR, Lee MH, Kong DS, Seol HJ, Nam DH, Sun JM, et al. : Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer. J Neurooncol 125 : 331-338, 2015 https://doi.org/10.1007/s11060-015-1915-x
  12. Choi YL, Sun JM, Cho J, Rampal S, Han J, Parasuraman B, et al. : EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One 8 : e56011, 2013 https://doi.org/10.1371/journal.pone.0056011
  13. Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, et al. : The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 116 : 978-983, 2012 https://doi.org/10.3171/2012.2.JNS111353
  14. Cortot AB, Italiano A, Burel-Vandenbos F, Martel-Planche G, Hainaut P : KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 116 : 2682-2687, 2010 https://doi.org/10.1002/cncr.25014
  15. Galluzzi S, Payne PM : Brain metastases from primary bronchial carcinoma: a statistical study of 741 necropsies. Br J Cancer 10 : 408-414, 1956 https://doi.org/10.1038/bjc.1956.47
  16. Harris S, Chan MD, Lovato JF, Ellis TL, Tatter SB, Bourland JD, et al. : Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer. Int J Radiat Oncol Biol Phys 83 : e53-59, 2012 https://doi.org/10.1016/j.ijrobp.2011.05.041
  17. Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, et al. : Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget 6 : 18945-18955, 2015
  18. Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, et al. : Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 119 : 2754-2764, 2013 https://doi.org/10.1002/cncr.28132
  19. Knights EM Jr : Metastatic tumors of the brain and their relation to primary and secondary pulmonary cancer. Cancer 7 : 259-265, 1954 https://doi.org/10.1002/1097-0142(195403)7:2<259::AID-CNCR2820070208>3.0.CO;2-C
  20. Lee HY, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, et al. : Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. Lung Cancer 79 : 40-45, 2013 https://doi.org/10.1016/j.lungcan.2012.10.002
  21. Lee S, Kim Y, Sun JM, Choi YL, Kim JG, Shim YM, et al. : Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol 137 : 1203-1211, 2011 https://doi.org/10.1007/s00432-011-0986-0
  22. Likhacheva A, Pinnix CC, Parikh NR, Allen PK, McAleer MF, Chiu MS, et al. : Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 85 : 656-661, 2013 https://doi.org/10.1016/j.ijrobp.2012.05.047
  23. Luo D, Ye X, Hu Z, Peng K, Song Y, Yin X, et al. : EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol 35 : 2437-2444, 2014 https://doi.org/10.1007/s13277-013-1323-9
  24. Luo S, Chen L, Chen X, Xie X : Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget 6 : 16725-16734, 2015
  25. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. : Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362 : 2380-2388, 2010 https://doi.org/10.1056/NEJMoa0909530
  26. Magilligan DJ Jr, Duvernoy C, Malik G, Lewis JW Jr, Knighton R, Ausman JI : Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years' experience. Ann Thorac Surg 42 : 360-364, 1986 https://doi.org/10.1016/S0003-4975(10)60536-X
  27. Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, et al. : Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 119 : 1491-1494, 2006 https://doi.org/10.1002/ijc.21940
  28. Mekhail T, Sombeck M, Sollaccio R : Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. Curr Oncol Rep 13 : 255-258, 2011 https://doi.org/10.1007/s11912-011-0180-1
  29. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. : Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11 : 121-128, 2010 https://doi.org/10.1016/S1470-2045(09)70364-X
  30. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. : Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 : 947-957, 2009 https://doi.org/10.1056/NEJMoa0810699
  31. Newman SJ, Hansen HH: Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 33 : 492-496, 1974 https://doi.org/10.1002/1097-0142(197402)33:2<492::AID-CNCR2820330225>3.0.CO;2-O
  32. Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, et al. : The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29 : 711-717, 1994 https://doi.org/10.1016/0360-3016(94)90558-4
  33. Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, et al. : Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 27 : 411-417, 2009 https://doi.org/10.1200/JCO.2008.18.3251
  34. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. : A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322 : 494-500, 1990 https://doi.org/10.1056/NEJM199002223220802
  35. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. : Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13 : 239-246, 2012 https://doi.org/10.1016/S1470-2045(11)70393-X
  36. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A : Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94 : 2698-2705, 2002 https://doi.org/10.1002/cncr.10541
  37. Sorensen JB, Hansen HH, Hansen M, Dombernowsky P : Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6 : 1474-1480, 1988 https://doi.org/10.1200/JCO.1988.6.9.1474
  38. Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, et al. : A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85 : 1312-1318, 2013 https://doi.org/10.1016/j.ijrobp.2012.11.042
  39. Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, et al. : HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 15 : 4829-4837, 2009 https://doi.org/10.1158/1078-0432.CCR-08-2921
  40. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. : Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15 : 387-395, 2014 https://doi.org/10.1016/S1470-2045(14)70061-0
  41. Zhuang H, Wang J, Zhao L, Yuan Z, Wang P : The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma. Int J Cancer 133 : 2277-2283, 2013 https://doi.org/10.1002/ijc.28290
  42. Zhuang HQ, Sun J, Yuan ZY, Wang J, Zhao LJ, Wang P, et al. : Radiosensitizing effects of gefitinib at different administration times in vitro. Cancer Sci 100 : 1520-1525, 2009 https://doi.org/10.1111/j.1349-7006.2009.01190.x

Cited by

  1. Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery vol.64, pp.2, 2021, https://doi.org/10.3340/jkns.2020.0135